For April 2025, the editors of AACR's 10 journals highlighted studies on evolution in glioblastoma, new cancer treatment approaches, and more.
The FDA has approved avutometinib and defactinib for certain patients with KRAS-mutated low-grade serous ovarian cancer. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to avutometinib and defactinib (Avmapki Fakzynja Co-pack)...
Immunotherapy may treat some early-stage cancer patients without the need for surgery, and exercise found to counter many side effects of cancer treatment.
Adding pembrolizumab before and after surgery to standard of care improved outcomes in patients with previously untreated head and neck cancer.
People with metabolic syndrome may have elevated risk for breast cancer mortality, and immunotherapy keeps lung cancer at bay even after discontinuing treatment.
The FDA has approved penpulimab-kcqx for certain patients with nasopharyngeal carcinoma. The U.S. Food and Drug Administration (FDA) has approved penpulimab-kcqx in combination with chemotherapy for the first-line treatment of patients with nonkeratinizing nasopharyngeal carcinoma...
A recently approved first-line therapy and novel insights into optimizing treatment strategies may offer new options for esophageal cancer patients.
The test, which analyzes urine for 18 cancer-specific genes, ruled out the need for biopsy in men with elevated PSA without a digital rectal exam.
Gaps in goals-of-care discussions may harm young adults with cancer, and 1 in 6 participants in phase II trials get treatments that are eventually approved by the FDA.
A congressional forum hosted by Senators Tammy Baldwin and Peter Welch examined how NIH funding cuts could impact cancer and other diseases.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More